SynAct Pharma has signed its first commercial partnership for its drug candidate resomelagon. Under the agreement, the Swedish company and the Brazilian pharmaceutical company Hipolabor will co-develop and commercialize the drug for the treatment of dengue in Brazil, one of the world’s largest dengue markets.

Finnish pharmaceutical company Orion has upgraded its full-year 2026 outlook for both net sales and operating profit, as royalty income has grown faster than expected so far this year.

The partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care.

Norwegian medtech company Medistim reported record third-quarter revenue of NOK 210.0 million, up 25.9% from NOK 166.8 million a year earlier. Operating profit rose 55.7% to NOK 63.1 million, and the board decided on the company’s first quarterly dividend, NOK 2.50 per share.

Episurf Medical has signed a letter of intent with Canada’s Oligo Medic for the possible sale of its medical technology business, as the Swedish company shifts its focus to real estate.

Swedish medtech company Getinge raised its adjusted EBITA margin to 15.1% in the third quarter of 2026, from 13.1% a year earlier, while organic sales grew 2.1%. The company kept its forecast of 3–5% organic sales growth for the full year.

The US Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI, Alvotech’s biosimilar to Humira, that more than doubles drug substance output per batch at the company’s facility in Reykjavik.

Alvotech and its partner Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to the high-dose retinal disease drug Eylea 8 mg. According to the companies, it is the first known submission of its kind worldwide.

The Drug Discovery and Development (DDD) platform at SciLifeLab has completed the first GMP-compatible cell line developed within BRIDGE Sweden, a national initiative to strengthen Sweden’s capacity for biologics development. The top-performing clones produce more than seven grams of monoclonal antibody per liter.

Forska!Sverige has established a new entrepreneurship award in memory of inventor and entrepreneur Leif Lundblad. The first recipient is Ulf Landegren, Professor of Molecular Medicine at Uppsala University, who has built several successful life science companies while helping other researchers do the same.

Karolinska Institutet researchers Tim Baker and Carl Otto Schell have received the Lancet–Elsevier Foundation Evidence to Impact Award for Essential Emergency and Critical Care (EECC), a set of 40 basic treatments for critically ill patients on regular hospital wards.

A new international study led from Lund University shows that brain changes associated with Alzheimer’s disease may affect the prognosis in ALS. In the long term, the findings could lead to more reliable individual prognoses and better-designed clinical trials.